Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: J Neurooncol. 2016 Jun 7;129(1):147–154. doi: 10.1007/s11060-016-2157-2

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2a. Overall survival from initial tumor diagnosis by IDH1 mutation status

Patients with an IDH1 mutation were found to have a significantly longer median OS than patients with an IDH1 wildtype tumor (83 months vs. 22 months) from initial tumor diagnosis. ( E/N- E stands for events and N is total number of patients).

Figure 2b. Time from initial tumor diagnosis to GB diagnosis by IDH Mutation status

Patients initially diagnosed with a low grade or anaplastic glioma with an IDH1 mutation were found to have a significantly longer time (66 months vs. 16 months) from initial tumor diagnosis to GB diagnosis than patients initially diagnosed with a low grade or anaplastic glioma with an IDH1 wildtype tumor. ( E/N- E stands for events and N is total number of patients).

Figure 2c. Progression free survival from recurrent GB trial by IDH Mutation status

Patients with IDH1 mutations were not found to have a significantly longer median PFS (3.5 months vs. 3.6 months) than patients with IDH1 wildtype tumors from the start of recurrent GB trials. ( E/N- E stands for events and N is total number of patients).

Figure 2d. Overall survival from recurrent GB trial by IDH Mutation status

Patients with IDH1 mutations were not found to have a significantly longer median OS (9.6 months vs.8.6 months) than patients with IDH1 wildtype tumors from the start of recurrent GB trials. ( E/N- E stands for events and N is total number of patients).